-
To many who observe the organ transplant arena, it's both a simple and yet complex reckoning of supply and demand.
-
Monir Moniruzzaman has seen the kind of poverty that would drive a desperate individual to sell his or her organ.
-
Compassion & Choices, an end-of-life rights group, says that it is "alarmed" by a newly revised Ethical and Religious Directive approved in November by the United States Conference of Catholic Bishops.
-
As Medical Ethics Advisor reported in December, one of the sessions held at the annual conference in Washington, DC, of the American Society of Bioethics and Humanities in October was on the top developments in bioethics in 2009.
-
The Centers for Medicare & Medicaid Services announced in early December 2009 its final decision to cover Human Immunodeficiency Virus (HIV) infection screening for Medicare beneficiaries who are at increased risk for the infection.
-
Technological advances in medicine have the capability of helping health care providers to prolong life for patients faced with a terminal illness or injury.
-
Most physicians reported in a national survey that they would discuss end-of-life options with a terminally ill patient only when there were no more treatments to offer that patient not when the patient was still feeling well, according to a study published online in CANCER, a peer-reviewed journal of the American Cancer Society, in January.
-
As medical scientists and engineers in the health care arena pursue advances in drugs and technologies, is now the time to think more critically about these new technologies and how to address future implications for say, the ramifications of genetic screening and designer babies?
-
When the University of Michigan Health System's chief risk officer arrived in 2001, he had already mapped out to institutional leaders an architecture for risk management and medical error disclosure that would dramatically change the system's liability expenses, as well as its approach to patient safety.
-
Some of the thorniest questions that IRBs face are those for which there are no clear-cut answers opinions may vary, arguments on both sides may be compelling, regulatory guidance may be scanty.
